Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytosorbents Co. stock logo
CTSO
Cytosorbents
$1.07
-2.7%
$1.05
$0.70
$1.61
$66.88M1.17143,834 shs16,176 shs
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
$30.22
+0.3%
$31.60
$25.86
$39.08
$269.02M1.4725,262 shs16,781 shs
Neuronetics, Inc. stock logo
STIM
Neuronetics
$4.19
+2.9%
$4.26
$0.52
$5.92
$267.87M1.97686,171 shs639,976 shs
ZimVie Inc. stock logo
ZIMV
ZimVie
$9.38
+2.0%
$11.31
$8.56
$22.40
$261.21M2.14221,736 shs116,019 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytosorbents Co. stock logo
CTSO
Cytosorbents
-2.73%+4.90%+3.88%+3.88%+21.73%
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
+0.33%+5.33%-15.33%-20.72%-7.30%
Neuronetics, Inc. stock logo
STIM
Neuronetics
+2.95%+11.14%-10.28%+75.31%+8.55%
ZimVie Inc. stock logo
ZIMV
ZimVie
+1.96%+1.41%-18.36%-34.54%-41.56%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cytosorbents Co. stock logo
CTSO
Cytosorbents
1.5176 of 5 stars
3.52.00.00.01.70.00.6
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
1.2853 of 5 stars
3.51.00.00.00.01.70.6
Neuronetics, Inc. stock logo
STIM
Neuronetics
1.894 of 5 stars
3.32.00.00.02.01.70.6
ZimVie Inc. stock logo
ZIMV
ZimVie
2.5798 of 5 stars
3.53.00.00.02.91.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cytosorbents Co. stock logo
CTSO
Cytosorbents
3.00
Buy$4.67336.14% Upside
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
3.00
Buy$48.5060.49% Upside
Neuronetics, Inc. stock logo
STIM
Neuronetics
2.67
Moderate Buy$5.5031.26% Upside
ZimVie Inc. stock logo
ZIMV
ZimVie
3.00
Buy$19.50107.89% Upside

Current Analyst Ratings Breakdown

Latest CTSO, STIM, SMTI, and ZIMV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$16.00
4/9/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/9/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/3/2025
Cytosorbents Co. stock logo
CTSO
Cytosorbents
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.00
4/1/2025
Cytosorbents Co. stock logo
CTSO
Cytosorbents
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/26/2025
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$46.00 ➝ $46.00
3/26/2025
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$50.00 ➝ $51.00
3/13/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
3/5/2025
Neuronetics, Inc. stock logo
STIM
Neuronetics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$5.00 ➝ $8.00
2/27/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
2/25/2025
Cytosorbents Co. stock logo
CTSO
Cytosorbents
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
(Data available from 4/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cytosorbents Co. stock logo
CTSO
Cytosorbents
$35.59M1.88N/AN/A$0.52 per share2.06
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
$86.67M3.10N/AN/A$5.22 per share5.79
Neuronetics, Inc. stock logo
STIM
Neuronetics
$74.89M3.68N/AN/A$1.18 per share3.55
ZimVie Inc. stock logo
ZIMV
ZimVie
$449.75M0.58$3.39 per share2.77$15.43 per share0.61
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cytosorbents Co. stock logo
CTSO
Cytosorbents
-$28.51M-$0.38N/AN/AN/A-49.47%-118.54%-42.31%5/8/2025 (Estimated)
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
-$4.30M-$1.14N/AN/AN/A-10.71%-19.86%-10.91%5/12/2025 (Estimated)
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$30.19M-$1.37N/AN/AN/A-50.09%-141.24%-32.77%5/6/2025 (Estimated)
ZimVie Inc. stock logo
ZIMV
ZimVie
-$393.28M-$0.95N/AN/A-77.31%2.90%1.17%5/14/2025 (Estimated)

Latest CTSO, STIM, SMTI, and ZIMV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
-$0.31N/AN/AN/A$23.48 millionN/A
5/8/2025Q1 2025
Cytosorbents Co. stock logo
CTSO
Cytosorbents
-$0.08N/AN/AN/A$9.01 millionN/A
5/6/2025Q1 2025
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$0.13N/AN/AN/A$29.07 millionN/A
3/31/2025Q4 2024
Cytosorbents Co. stock logo
CTSO
Cytosorbents
-$0.07-$0.03+$0.04-$0.14$10.09 million$9.20 million
3/25/2025Q4 2024
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
-$0.19-$0.18+$0.01-$0.18$22.75 million$26.31 million
2/26/2025Q4 2024
ZimVie Inc. stock logo
ZIMV
ZimVie
$0.25$0.27+$0.02-$0.43$113.67 million$111.52 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cytosorbents Co. stock logo
CTSO
Cytosorbents
N/AN/AN/AN/AN/A
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
N/AN/AN/AN/AN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
N/AN/AN/AN/AN/A
ZimVie Inc. stock logo
ZIMV
ZimVie
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cytosorbents Co. stock logo
CTSO
Cytosorbents
1.06
1.97
1.58
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
0.76
2.23
2.02
Neuronetics, Inc. stock logo
STIM
Neuronetics
4.90
3.16
2.87
ZimVie Inc. stock logo
ZIMV
ZimVie
0.57
1.94
1.38

Institutional Ownership

CompanyInstitutional Ownership
Cytosorbents Co. stock logo
CTSO
Cytosorbents
32.87%
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
8.10%
Neuronetics, Inc. stock logo
STIM
Neuronetics
53.59%
ZimVie Inc. stock logo
ZIMV
ZimVie
95.63%

Insider Ownership

CompanyInsider Ownership
Cytosorbents Co. stock logo
CTSO
Cytosorbents
6.60%
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
54.10%
Neuronetics, Inc. stock logo
STIM
Neuronetics
9.80%
ZimVie Inc. stock logo
ZIMV
ZimVie
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cytosorbents Co. stock logo
CTSO
Cytosorbents
22062.50 million51.07 millionOptionable
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
608.90 million4.01 millionNot Optionable
Neuronetics, Inc. stock logo
STIM
Neuronetics
18065.82 million27.37 millionOptionable
ZimVie Inc. stock logo
ZIMV
ZimVie
2,70027.85 million26.77 millionOptionable

Recent News About These Companies

ZimVie announces launch of its Immediate Molar Implant system in US
ZimVie launches molar implant system
What is B. Riley's Forecast for ZimVie Q1 Earnings?
Needham Remains a Hold on ZimVie Inc (ZIMV)
ZimVie initiated with a Buy at B. Riley

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cytosorbents stock logo

Cytosorbents NASDAQ:CTSO

$1.07 -0.03 (-2.73%)
Closing price 04/23/2025 04:00 PM Eastern
Extended Trading
$1.07 0.00 (0.00%)
As of 04/23/2025 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Sanara MedTech stock logo

Sanara MedTech NASDAQ:SMTI

$30.22 +0.10 (+0.33%)
Closing price 04/23/2025 04:00 PM Eastern
Extended Trading
$30.39 +0.17 (+0.56%)
As of 04/23/2025 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

Neuronetics stock logo

Neuronetics NASDAQ:STIM

$4.19 +0.12 (+2.95%)
Closing price 04/23/2025 04:00 PM Eastern
Extended Trading
$4.26 +0.07 (+1.79%)
As of 04/23/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

ZimVie stock logo

ZimVie NASDAQ:ZIMV

$9.38 +0.18 (+1.96%)
Closing price 04/23/2025 04:00 PM Eastern
Extended Trading
$9.39 +0.01 (+0.11%)
As of 04/23/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ZimVie Inc., together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment. The company offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; and patient-specific restorative solutions, such as abutments, bars, implant bridges, and hybrid restorations under the BellaTek brand name. It provides bone grafts, barrier membranes, and collagen wound care products; virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and intra-oral scanners; and Implant Concierge, a web-based treatment planning and surgery guide service. In addition, the company designs, manufactures, and distributes spinal fusion implants, instrumentation for various spinal procedures, biologics, and bone healing technologies. Further, it provides MIS solutions that deliver implant and instrumentation systems; and motion preservation solutions that offer non-fusion alternatives for cervical disc implant or growth modulation for anterior vertebral body tethering. The company sells its products to oral surgeons, dental specialists, general dentists, dental laboratories, and other dental organizations, including DSOs, as well as educational, medical, and governmental entities, hospitals, and surgery centers through direct sales representatives, agents, and distributors. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.